# TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes

> **NCT01829464** · PHASE3 · TERMINATED · sponsor: **Takeda** · enrollment: 90 (actual)

## Conditions studied

- Diabetes

## Interventions

- **DRUG:** Placebo
- **DRUG:** TAK-875
- **DRUG:** TAK-875

## Key facts

- **NCT ID:** NCT01829464
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-05
- **Primary completion:** 2014-02
- **Final completion:** 2014-03
- **Target enrollment:** 90 (ACTUAL)
- **Why stopped:** Due to potential concerns about liver safety (See Detailed Description)
- **Last updated:** 2016-06-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01829464

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01829464, "TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01829464. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*